Referenser Lipidrubbning

1. Socialstyrelsen. Nationella riktlinjer för hjärtsjukvården. 2008, kompletterade 2011. (socialstyrelsen.se) 
2. Socialstyrelsen. Nationella riktlinjer för strokesjukvård. 2009, kompletterade 2011. (socialstyrelsen.se)
3. Socialstyrelsen. Nationella riktlinjer för diabetesvården. 2010. (socialstyrelsen.se)
4. Läkemedelsverket. Förebyggande av aterosklerotisk hjärt­kärlsjukdom. 2006;3(17).
5. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul;32(14):1769­818. (escadrio.org)
6. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012 Jul;33(13):1635­701. (escadrio.org)
7. Heart Protection Study Collaborative Group. Effects on 11­year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high ­risk individuals: A randomised controlled trial. Lancet 2011; 387:2013­20.
8. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 2007;24(2­3):170­82.
9. Collins R, Armitage J, Parish S et al (HPS). Effects of cholesterol­lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high­risk conditions. Lancet 2004 Mar 6;363(9411):757­67.
10. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta­analysis of individual data from 27 randomised trials. Lancet 2012 Aug 11;380(9841):581­90.
11. Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; 1 (CD004816).
12. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L et al. Efficacy of cholesterol­lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta­analysis. Lancet 2008 Jan 12;371(9607):117­25.
13. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta ­analysis. Lancet 2010; 375:1875­84.
14. Ray KK, Seshasai SR, Erqou S et al. Statins and all-­cause mortality in high­risk primary prevention: a meta­analysis of 11 randomized control­ led trials involving 65,229 participants. Arch Intern Med 2010;170(12):1024­31.
15. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta­analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi:10.1136/bmj.b2376.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering in 20 536 high­risk individuals: a rando­mized placebocontrolled trial. Lancet 2002;360:7­22.
17. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.
18. Armitage J, Bowman L, Wallendszus K et al (SEARCH). Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double­blind randomised trial. Lancet 2010 Nov 13;376(9753):1658­69.
19. Emberson J, Bennett D, Link E et al. C­reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Lancet 2011 Feb 5;377(9764):469­76.
20. Afilalo J, Duque G, Steele R et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta­ analysis. J Am Cardiol 2008;51(1):37­45.
21. Ridker PM, Danielson E, Fonseca FA et al (JUPITER). Rosuvastatin to prevent vascular events in men and women with elevated C­reactive protein. N Engl J Med 2008;359(21):2195­207.
22. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495­504.
23. Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA­RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.J Am Coll Cardiol 2009;54:558­65.
24. Patti G, Cannon CP, Murphy SA et al. Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention/ Clinical Perspective: A Collaborative Patient­ Level Meta­Analysis of 13 Randomized Studies. Circulation 2011;123:1622­1632.
25. Kastelein JJ, Akdim F, Stroes ES et al (ENHANCE). Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358(14):1431­43.
26. Rossebø AB, Pedersen TR, Boman K et al (SEAS). Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359(13):1343­56.
27. Baigent C, Landray MJ, Reith C et al (SHARP). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo­controlled trial. Lancet 2011 Jun 25;377(9784):2181­92.
28. Boden WE, Probstfield JL, Anderson T et al (AIM­HIGH). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 Dec 15;365(24):2255­67.
29. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta­ analysis of randomized statins trials. Lancet 2010; 375:735­42.
30. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive­ dose compared with moderate ­dose statin therapy. A Meta­analysis. JAMA 2011;305:2556­64.
31. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M et al. Metaanalysis of drug­ induced adverse events associated with intensivedose statin therapy. Clin Therapy 2007 Feb;29(2):253­60.
32. Kjekshus J, Apetrei E, Barrios V et al (CORONA). Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248­ 61.
33. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(8A):77C­81C.
34. Amarenco P, Bogousslavsky J, Callahan A et al (SPARCL). High­dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355(6):549­59.
35. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120(4):833­43.
36. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta­analysis. JAMA 2006;295(1):74­80.
37. The effects of cholesterol lowering with simvastatin on cause­specific mortality and on cancer incidence in 20,536 high­risk people: a randomised placebo­controlled trial. BMC Med 2005;3:6.
38. Christopher P. Cannon, M.D., Michael A. Blazing, M.D., Robert P. Giugliano, M.D et al. Ezetimibe Added to Statin Therapy after Acute Coro­ nary Syndromes. N Engl J Med 2015; 372:2387­2397.
39. Att förebygga aterosklerotisk hjärt­kärlsjukdom med läkemedel – behandlingsrekommendation Information från Läkemedelsverket 2014:(25) 5
40. HOPE­3 Yusuf S, et al. ”Blood ­Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease”. The New England Journal of Medicine. 2016. 374(21):2032­2343
41. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. Epub 17 mar 2017. doi: 10.1056/NEJMoa1615664.
42. Schwartz et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syn­ drome. N Engl J Med. 2018;379(22):2097­107.